
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths. “Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN on Wednesday. “Patients who believe that they’re getting access to a safe product, and they believe they’re getting semaglutide … I know for a fact that they are not getting semaglutide, because there’s only one semaglutide, and that’s produced by Novo Nordisk, and we don’t sell that to others.” Compounded drugs are made by pharmacies or manufacturers other than the companies that make approved versions of those medicines, and they typically are allowed when there is a shortage of those drugs. Semaglutide, and other GLP-1 drugs like it, have experienced shortages in the past two years as millions of Americans have turned to the medications for help with significant weight loss. While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply — the lowest dose of Wegovy — is now listed as available, CNN reported. “We’re collaborating with the FDA, and I think they’re looking into what are some of the considerations they have… read on > read on >